Le Lézard
Classified in: Health
Subject: ATY

Hagens Berman Notifies Investors That Lost Money in MacroGenics (MGNX)


SAN FRANCISCO, Sept. 18, 2019 /PRNewswire/ -- Hagens Berman notifies MGNX investors of a securities fraud lawsuit filed against MacroGenics, Inc. (MGNX).

Hagens Berman Sobol Shapiro LLP

CLASS PERIOD: Feb. 6, 2019 ? June 3, 2019
LEAD PLAINTIFF DEADLINE:
Nov. 12, 2019
Email: [email protected]
Visit: https://www.hbsslaw.com/investor-fraud/mgnx 
Call: Reed Kathrein, who is leading the firm's investigation: 510-725-3000

MGNX Securities Class Action:

According to the Complaint, Defendants concealed adverse information obtained during MacroGenics' clinical trial evaluating margetuximab, a potential breast cancer treatment.  Specifically, as early as October 2018, Defendants knew but omitted to disclose that (1) the progression-free survival ("PFS") of patients in the trial was negligible, and (2) the overall survival ("OS") was not statistically significant.  The market learned the truth on June 4, 2019, when MacroGenics disclosed the lackluster PFS and OS results.  This news drove the price of MGNX shares sharply lower that day.

If you invested in MacroGenics between Feb. 6, 2019 and June 3, 2019 and suffered significant losses (in excess of $50,000) you may qualify to be a lead plaintiff ? one who selects and oversees the attorneys prosecuting the case.  Contact Hagens Berman immediately to obtain additional information about this case or being a lead plaintiff.

"We are focused on investors' losses and the extent to which Defendants' statements may have been misleading," said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding MacroGenics should consider their options to help in the investigation or take advantage of the SEC whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email [email protected].

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys.  The firm represents investors, whistleblowers, workers and consumers in complex litigation.  More about the firm and its successes is located at hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 510-725-3000

 

SOURCE Hagens Berman Sobol Shapiro LLP


These press releases may also interest you

at 09:00
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of A5374, a phase 1/2a study evaluating the safety, tolerability, and antiviral effect of a novel combination regimen that includes...

at 09:00
PureTalk, a nationwide cell phone service provider offering premium wireless service at a fair price on the nation's most dependable 5G network, today celebrates over $100,000 customer donations to the America's Warrior Partnership (AWP). Since...

at 09:00
Amid growing concerns about a medical crisis as a result of acute conflict between the government...

at 09:00
On 5 April 2024, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Board of Directors, with the support of the authorization granted by the annual general meeting held on 17 May 2023, had resolved on a rights issue of units,...

at 09:00
Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced that Galentm Breast HER2 has been named a bronze winner of the 2024 Edison Awards in the Diagnostic Technologies category. The awards, named after inventor...

at 09:00
Collective bargaining for registered nurses (RNs) and health-care professionals with the province's for-profit nursing homes has broken down just three days into five days of scheduled negotiations, with no deal reached, says the Ontario Nurses'...



News published on and distributed by: